Unima

Unima is decentralizing rapid testing across industries by taking diagnostics out of the lab to the place these are needed the most to secure a timely diagnostic for everyone, anywhere.

Unima is solving is the centralization of lab testing, which limits the access to a timely diagnostic for billions. Current technology for diagnostics is very precise and can detect almost any disease known, but the problem is these require labs with expensive equipment and specialized technicians making lab testing impossible to scale up to provide universal and timely access to diagnostics.

To solve this problem Unima developed Find, a rapid testing technology platform for real time diagnostics which allows anyone to diagnose a disease directly where it is needed, without using lab equipment, with results in 15 minutes or less and at a very low cost. With Find anyone can have access to a timely diagnostic even in the most remote areas of the world.

The Find platform uses shark antibodies modified with genetic engineering to detect disease biomarkers in blood, saliva, urine or water samples. These shark antibodies are used in microfluidic cards and generate a visual reactions when in contact with specific biomarkers of the disease to be tested. Then to evaluate the result of the test, a picture of the testing card is taken with the proprietary Xplora smartphone app which runs image analysis process and neural network algorithms to generate an inmediate result. Then this result,along with contextual information like geolocation, date and time, is sent to a cloud server where it can be used for real time disease tracking.

Unima headquartered in North America, operates in the Biotechnology, Health Care, Health Diagnostics sector. The company focuses on Biotechnology and has secured $169.4M in funding across 84 round(s). With a team of 11-50 employees, Unima is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Unima, raised $1.9M. Discover more about their projects, partnerships, and impact on our platform.